This post is from a suggested group
The Heterogeneity of Refractory Angina: Why a ‘One-Size-Fits-All’ Approach Fails in the Treatment Market
Description: This post explains why refractory angina patients are a heterogeneous group with varied underlying causes (e.g., epicardial vs. microvascular disease) and the resulting complexity for treatment development.
Blog Post 7/10
One of the greatest impediments to therapeutic development in the Refractory Angina Treatment Market is the remarkable heterogeneity of the patient population. Refractory angina (RA) is not a single disease entity but a clinical syndrome encompassing a diverse group of patients who share only the persistent, debilitating nature of their chest pain. The underlying pathophysiology can vary significantly, ranging from macrovascular causes like diffuse, non-revascularizable epicardial coronary artery disease (CAD) to microvascular issues, or even non-cardiac chest pain misattributed to the heart.
This lack of a single, unified etiology means that a "one-size-fits-all" treatment strategy is doomed to fail. A therapy effective for a patient with severe…